Nicolas Peilleron1, Arnaud Seigneurin2,3, Caroline Herault3, Camille Verry4, Michel Bolla4, Jean-Jacques Rambeaud1, Jean-Luc Descotes1,2, Jean-Alexandre Long1,2, Gaelle Fiard5,6. 1. Department of Urology, Grenoble Alpes University Hospital, CS10217 Cedex 9, 38043, Grenoble, France. 2. Univ. Grenoble Alpes, CNRS, Grenoble INP, TIMC IMAG, Grenoble, France. 3. Department of Medical Assessment, Grenoble Alpes University Hospital, Grenoble, France. 4. Department of Radiotherapy, Grenoble Alpes University Hospital, Grenoble, France. 5. Department of Urology, Grenoble Alpes University Hospital, CS10217 Cedex 9, 38043, Grenoble, France. gfiard@chu-grenoble.fr. 6. Univ. Grenoble Alpes, CNRS, Grenoble INP, TIMC IMAG, Grenoble, France. gfiard@chu-grenoble.fr.
Abstract
PURPOSE: The Briganti nomogram can be used with a threshold of 5% to decide when to offer lymph node dissection during radical prostatectomy. The objective of the study was to assess the accuracy of the Briganti nomogram on intermediate-risk prostate cancer patients managed in a single academic department. METHODS: We retrospectively reviewed the files of all patients managed by radical prostatectomy (RP) and bilateral pelvic lymph node dissection (BPLND) in our center between 2005 and 2017. The overall accuracy of the model in predicting metastatic lymph node disease was quantified by the construction of a receiver-operator characteristic (ROC) curve. A calibration plot was drawn to represent the relationship between the predicted and observed frequencies. RESULTS: We included 285 patients, among whom 175 (61.4%) were classified as intermediate risk as defined by D'Amico. The median follow-up was 60 (34-93) months. Twenty-seven patients (9.5%) were diagnosed with lymph node metastases. The median number of lymph nodes removed was 10 (7-14). The mean Briganti score was 19.3% in patients with lymph node involvement (LNI) and 6.3% in patients without LNI. Focusing on intermediate-risk patients, 91(52%) and 84 (48%) had a Briganti score < 5% and ≥ 5%, respectively, among whom 6 (6.6%) and 7(8.3%) had lymph node metastases. The accuracy of the score was low for intermediate risk patients with an area under the curve (AUC) of 53.1% (95% CI 0.45-0.61). CONCLUSION: The Briganti nomogram in our retrospective cohort showed low accuracy for the prediction of lymph node involvement in an intermediate-risk prostate cancer population.
PURPOSE: The Briganti nomogram can be used with a threshold of 5% to decide when to offer lymph node dissection during radical prostatectomy. The objective of the study was to assess the accuracy of the Briganti nomogram on intermediate-risk prostate cancerpatients managed in a single academic department. METHODS: We retrospectively reviewed the files of all patients managed by radical prostatectomy (RP) and bilateral pelvic lymph node dissection (BPLND) in our center between 2005 and 2017. The overall accuracy of the model in predicting metastatic lymph node disease was quantified by the construction of a receiver-operator characteristic (ROC) curve. A calibration plot was drawn to represent the relationship between the predicted and observed frequencies. RESULTS: We included 285 patients, among whom 175 (61.4%) were classified as intermediate risk as defined by D'Amico. The median follow-up was 60 (34-93) months. Twenty-seven patients (9.5%) were diagnosed with lymph node metastases. The median number of lymph nodes removed was 10 (7-14). The mean Briganti score was 19.3% in patients with lymph node involvement (LNI) and 6.3% in patients without LNI. Focusing on intermediate-risk patients, 91(52%) and 84 (48%) had a Briganti score < 5% and ≥ 5%, respectively, among whom 6 (6.6%) and 7(8.3%) had lymph node metastases. The accuracy of the score was low for intermediate risk patients with an area under the curve (AUC) of 53.1% (95% CI 0.45-0.61). CONCLUSION: The Briganti nomogram in our retrospective cohort showed low accuracy for the prediction of lymph node involvement in an intermediate-risk prostate cancer population.
Authors: Christopher U Jones; Daniel Hunt; David G McGowan; Mahul B Amin; Michael P Chetner; Deborah W Bruner; Mark H Leibenhaut; Siraj M Husain; Marvin Rotman; Luis Souhami; Howard M Sandler; William U Shipley Journal: N Engl J Med Date: 2011-07-14 Impact factor: 91.245
Authors: Alberto Briganti; Felix K-H Chun; Andrea Salonia; Giuseppe Zanni; Vincenzo Scattoni; Luc Valiquette; Patrizio Rigatti; Francesco Montorsi; Pierre I Karakiewicz Journal: Eur Urol Date: 2006-02-17 Impact factor: 20.096
Authors: Alberto Briganti; Steven Joniau; Paolo Gontero; Firas Abdollah; Niccolò M Passoni; Bertrand Tombal; Giansilvio Marchioro; Burkhard Kneitz; Jochen Walz; Detlef Frohneberg; Chris H Bangma; Markus Graefen; Alessandro Tizzani; Bruno Frea; R Jeffrey Karnes; Francesco Montorsi; Hein Van Poppel; Martin Spahn Journal: Eur Urol Date: 2011-12-02 Impact factor: 20.096
Authors: Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Maria De Santis; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Vsevolod B Matveev; Paul C Moldovan; Roderick C N van den Bergh; Thomas Van den Broeck; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Philip Cornford Journal: Eur Urol Date: 2016-08-25 Impact factor: 20.096
Authors: Anna Bill-Axelson; Lars Holmberg; Hans Garmo; Jennifer R Rider; Kimmo Taari; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Anders Spångberg; Ove Andrén; Juni Palmgren; Gunnar Steineck; Hans-Olov Adami; Jan-Erik Johansson Journal: N Engl J Med Date: 2014-03-06 Impact factor: 91.245
Authors: Nicola Frego; Marco Paciotti; Nicolò Maria Buffi; Davide Maffei; Roberto Contieri; Pier Paolo Avolio; Vittorio Fasulo; Alessandro Uleri; Massimo Lazzeri; Rodolfo Hurle; Alberto Saita; Giorgio Ferruccio Guazzoni; Paolo Casale; Giovanni Lughezzani Journal: Front Surg Date: 2022-02-25
Authors: Zhaoxia Zhang; Chenghao Zhanghuang; Jinkui Wang; Tao Mi; Jiayan Liu; Xiaomao Tian; Liming Jin; Dawei He Journal: Front Public Health Date: 2022-07-12